Sight Sciences (NASDAQ:SGHT) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Sight Sciences (NASDAQ:SGHT) posted its quarterly earnings data on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01), Zacks reports. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. Sight Sciences updated its FY 2025 guidance to EPS.

Sight Sciences Stock Performance

Shares of NASDAQ SGHT traded down $0.05 during midday trading on Wednesday, hitting $2.42. 306,586 shares of the company’s stock were exchanged, compared to its average volume of 250,793. Sight Sciences has a 12 month low of $2.29 and a 12 month high of $8.45. The company’s 50 day moving average price is $2.97 and its 200 day moving average price is $4.46. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $122.83 million, a PE ratio of -2.37 and a beta of 2.52.

Insider Buying and Selling at Sight Sciences

In related news, CEO Paul Badawi sold 24,819 shares of Sight Sciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $2.92, for a total transaction of $72,471.48. Following the completion of the sale, the chief executive officer now owns 5,676,331 shares of the company’s stock, valued at approximately $16,574,886.52. The trade was a 0.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold 63,014 shares of company stock valued at $197,295 in the last quarter. 28.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SGHT. Piper Sandler reaffirmed a “neutral” rating and set a $5.50 price target (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Morgan Stanley lowered their price target on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, November 11th. Citigroup cut their price target on shares of Sight Sciences from $4.60 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday. Lake Street Capital decreased their price objective on Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, January 15th. Finally, UBS Group decreased their price target on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Sight Sciences presently has a consensus rating of “Hold” and a consensus price target of $4.42.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.